$CBLL

Chao Xingjuan sold $776K of CBLL

Chao Xingjuan (President and CEO) sold 39,000 shares of Ceribell, Inc. (CBLL) at $19.90 ($0.78M total) across 3 trades on 2026-07-07 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Chao Xingjuan
Published Jul 9, 2026, 4:34 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 9, 2026, 4:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CBLL
Neutral
high confidence
Mentioned
$CBLL
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CBLLNeutralLow
01

Why it matters

The disclosure updates the record of insider activity but does not introduce new company fundamentals (no earnings, guidance, deal, or regulatory action).

02

Market read

Traders may monitor insider activity for sentiment, but the 10b5-1 framing and lack of fundamental catalysts suggest limited trading impact.

03

What to watch

The article does not state whether the sale was part of a broader pattern, tax planning, or diversification; it only provides the transaction details and post-sale holdings.

Relevance 4/10Novelty 3/10Timing: New Form 4 filed July 9, covering sales executed July 7.

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for Ceribell, Inc.

Company-level read

Ticker impact

$CBLLNeutralHigh confidence
Context

Ceribell CEO Chao Xingjuan filed a Form 4 selling 39,000 shares at $19.90 on a 10b5-1 plan, worth about $776K.

Expected impact

Likely minimal near-term impact; any effect would be sentiment-driven rather than fundamental.

Evidence & confidence

The filing specifies an S (open-market sale) executed under a pre-arranged 10b5-1 plan, with no accompanying operational or financial guidance changes disclosed in the text.

Market effects

No sector read-through is provided; this is company-specific insider transaction data only.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still be interpreted by some traders as a mild negative signal about near-term outlook.

Key entities

  • Ceribell, Inc.

    Company whose CEO insider sale is disclosed via SEC Form 4.

  • Chao Xingjuan

    President and CEO reporting an open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$EWHighAI 8/10

Weekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report Data

Edwards Lifesciences (EW) received FDA approval for a pediatric heart valve. Ceribell (CBLL) and SI-BONE (SIBN) cleared new software and spinal fusion systems. Teva (TEVA) added a biosimilar to its portfolio. AbbVie (ABBV) and Mirum (MIRM) gained FDA approvals for Parkinson's and rare disease treatments. Merck (MRK) withdrew a lung cancer drug filing. Sanofi (SNY) and Regeneron (REGN) expanded their immunology alliance.

$CBLLMedAI 8/10

Ceribell Receives FDA 510(k) Clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis

Ceribell, Inc. (Nasdaq: CBLL) received FDA 510(k) clearance for new software for its EEG system, enabling easier interpretation of brain activity trends. The update includes Alpha-Delta Ratio, Burst Suppression, and Amplitude-Integrated EEG monitoring, applicable to patients of all ages. The company expects to roll out the features in the first half of 2027.

$CBLLHigh

Ceribell Reports Second Quarter 2026 Financial Results

Ceribell, Inc. (CBLL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Ceribell Reports Second Quarter 2026 Financial Results Sunnyvale, Calif. – August 10, 2026 – CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today repor